12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 13h ago
Gainers
- Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion.
- SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7% to $6.0. The market value of their outstanding shares is at $51.6 million.
- Capricor Therapeutics (NASDAQ:CAPR) shares rose 11.51% to $9.24. The company's market cap stands at $481.9 million.
- Akari Therapeutics (NASDAQ:AKTX) shares rose 11.3% to $8.76. The company's market cap stands at $15.3 million.
- Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 11.23% to $4.95. The market value of their outstanding shares is at $42.9 million.
- Cardiol Therapeutics (NASDAQ:CRDL) shares moved upwards by 10.74% to $2.21. The market value of their outstanding shares is at $233.6 million.
Losers
- Electromed (AMEX:ELMD) stock fell 18.8% to $31.96 during Wednesday's regular session. The company's market cap stands at $325.7 million. The company's, Q4 earnings came out yesterday.
- Biodexa Pharmaceuticals (NASDAQ:BDRX) shares declined by 17.11% to $0.98. The company's market cap stands at $1.2 million.
- Generate Biomedicines (NASDAQ:GENB) stock declined by 16.71% to $16.98. The company's market cap stands at $2.5 billion.
- Akanda (NASDAQ:AKAN) shares decreased by 15.96% to $4.16. The company's market cap stands at $2.6 million.
- Profusa (NASDAQ:PFSA) stock declined by 15.4% to $4.23. The company's market cap stands at $3.0 million. The company's, Q2 earnings came out 4 days ago.
- USBC (AMEX:USBC) shares decreased by 13.59% to $0.45. The market value of their outstanding shares is at $200.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.